2,187
Views
5
CrossRef citations to date
0
Altmetric
Articles

Investigation on the active ingredient and mechanism of Cannabis sativa L. for treating epilepsy based on network pharmacology

, , &
Pages 994-1009 | Received 18 Mar 2021, Accepted 07 Jun 2021, Published online: 28 Jun 2021

Figures & data

Figure 1. Workflow of the network pharmacological investigation on the potential use of cannabis in EP treatment.

Figure 1. Workflow of the network pharmacological investigation on the potential use of cannabis in EP treatment.

Figure 2. Venn diagram between cannabis targets and epileptic targets.

Figure 2. Venn diagram between cannabis targets and epileptic targets.

Table 1. 235 potential active ingredients and ADME parameters of Cannabis sativa L.

Table 2. Information on 116 potential targets of Cannabis sativa L.

Figure 3. C-T network. (A) The compound – target network of all compounds. (B) The compound – target network of cannabinoids.

Figure 3. C-T network. (A) The compound – target network of all compounds. (B) The compound – target network of cannabinoids.

Figure 4. Enrichment analysis of potential targets from main active ingredients of cannabis. (A) Gene Ontology terms for molecular function. (B) Gene Ontology terms for biological process. (C) Gene Ontology terms for cellular component. (D) KEGG pathways.

Figure 4. Enrichment analysis of potential targets from main active ingredients of cannabis. (A) Gene Ontology terms for molecular function. (B) Gene Ontology terms for biological process. (C) Gene Ontology terms for cellular component. (D) KEGG pathways.

Figure 5. The T–P network.

Figure 5. The T–P network.

Figure 6. ‘EP’ pathway. (A) Distribution of targets of cannabis on compressed ‘EP pathway’. (B) Calcium signalling pathway. (C) MAPK signalling pathway. (D) Synaptic connections.

Figure 6. ‘EP’ pathway. (A) Distribution of targets of cannabis on compressed ‘EP pathway’. (B) Calcium signalling pathway. (C) MAPK signalling pathway. (D) Synaptic connections.

Figure 7. Schematic 3 D representation that the molecular docking model. (A) Binding mode of M10 to GSK3B. (B) Binding mode of M46 to MAPK10. (C) Binding mode of M54 to CNR1. (D) Binding mode of M54 to AR. (E) Binding mode of M34 to ALB.

Figure 7. Schematic 3 D representation that the molecular docking model. (A) Binding mode of M10 to GSK3B. (B) Binding mode of M46 to MAPK10. (C) Binding mode of M54 to CNR1. (D) Binding mode of M54 to AR. (E) Binding mode of M34 to ALB.

Table 3. Molecule docking scores for potential active ingredients with targets.

Data availability

The data supporting the findings reported in this study are available from the corresponding author upon reasonable request.